June 14 (Reuters) – Eli Lilly and Co: * LILLY'S JAYPIRCA (PIRTOBRUTINIB) SIGNIFICANTLY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% WHEN ADDED TO A VENETOCLAX TIME-LIMITED REGIMEN IN PEOPLE
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Companies left China to dodge tariffs. Now some are heading back
By Ellen Zhang and Marius Zaharia BEIJING/HONG KONG, Sept 14 (Reuters) - A year after…
Meghan Markle shares first glimpse of family life in UK after return with Prince Harry, kids
London [UK], September 14 (ANI): Meghan Markle, the Duchess of Sussex, has shared the first…
Duroply launches DURO HDMMR™ – High Density Max Moisture Resistant Engineered Board
New Delhi [India], September 10: Duroply Industries Limited is expanding its existing product portfolio in…
